GlassScriptPhysician profile
Curtis E Bazemore
NPI 1477619831
$1,874.32
in general payments reported to CMS, 2019-2025
24 companies · $374 in 2025
The $374 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $165 · 2021: $160 · 2022: $300 · 2023: $308 · 2024: $321 · 2025: $374.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.22 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $252.35 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Genentech USA, INC. | $216.99 | 2019-2021 | |
| Amgen INC. | $163.80 | 2023-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $141.50 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $117.02 | 2022 | |
| Lilly USA, LLC | $79.57 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Idorsia Pharmaceuticals US INC | $51.35 | 2022-2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $49.95 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.32 | 2019 | |
| Abbvie INC. | $45.97 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $43.18 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $40.75 | 2024 | Voquezna |
| Eisai INC. | $34.72 | 2021 | |
| Amarin Pharma, INC. | $30.85 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $29.58 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.43 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.71 | 2022 | |
| Intra-Sana Laboratories | $17.06 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Esperion Therapeutics, INC. | $15.25 | 2021 | |
| Glaxosmithkline, LLC. | $14.90 | 2023 | Shingrix, Trelegy Ellipta |
| Lundbeck LLC | $14.58 | 2024 | Rexulti |
| Dexcom, INC. | $13.27 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Bazemore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.